The DNA repair protein DDB2 has been implicated in promoting cell cycle progression by regulating gene expression. DDB2 is selectively overexpressed in breast tumor cells that are non-invasive, but not in those that are invasive. We found that its overexpression in invasive human breast tumor cells limited their motility and invasiveness in vitro and blocked their ability to colonize lungs in vivo, defining a new function for DDB2 in malignant progression. 
Introduction
Development of metastatic disease is the primary cause of mortality in patients with breast cancer. This is a multistep event, comprising invasion of mammary carcinoma cells into the adjacent tissues, entry of tumor cells in the systemic circulation, extravasation to distant organs, and finally metastatic colonization, mainly in lungs, liver, bones and the central nervous system (1) . Despite significant advances in diagnosing and treating breast cancer, one of the major clinical and scientific problems which remain unresolved is the prediction of breast tumor progression toward metastasis. Also, identification of new predictive markers of metastatic development appears relevant.
We described recently that the Damaged DNA binding 2 (DDB2) protein, which was originally identified as an accessory factor in nucleotide excision repair of UV-induced DNA damage, is involved in breast tumor growth. DDB2 is overexpressed in nonmetastatic breast tumor cells and plays a role in their proliferation by favouring G1/S transition entry and their progression through the S phase of the cell cycle (2) . We reported that DDB2 stimulates the proliferation of nonmetastatic breast tumor cells, at least in part by maintaining a low basal expression of mitochondrial superoxide dismutase (MnSOD) through its binding to a specific and well characterized DNA sequence in the proximal promoter of the MnSOD gene (3) . In addition, in metastatic breast tumor cells DDB2 is not expressed and a high basal MnSOD level is observed, which is sharp in contrast to non metastatic cells. In these cells, the antioxidant enzyme was involved in the invasive ability of these cells through its control of matrix metalloprotease 9 (MMP-9) activity (4).
Based on these results, we hypothesized that the DDB2 protein might be involved in the control of cell migration, invasiveness and breast tumor progression. To verify this hypothesis, we studied the consequence of DDB2 overexpression in the invasive and metastatic properties of aggressive breast cancer cells. Here we demonstrate in vitro as well as 4 in vivo that DDB2 reduces significantly motility and invasiveness of metastatic breast cancer cells when its gene is overexpressed. We have identified that DDB2 plays this role through its involvement in Inhibitor kappa B alpha (IκBα) gene expression and in consequence in the negative control of constitutive nuclear factor-kappa B (NF-κB) activity. This latter binds to DNA as hetero-or homodimers that are composed of five possible proteins belonging to the Rel family (c-Rel, RelB and p65/RelA, p50 and p52), and which are maintained in a latent form in the cytoplasm through interaction with the inhibitory IκBα protein (5) . NF-κB transcription factor is constitutively activated in metastatic breast tumor cells and plays a role in their migration and invasive abilities by regulating the expression of target genes (6, 7) .
However, the molecular mechanism involved in the constitutive activation of NF-κB is not yet clearly defined in breast cancer. 
Materials and Methods

Plasmids and lentiviral particles
The pcDNA3(+) expression vector containing the DDB2 open reading frame cDNA was constructed as described previously (3) . Lentiviral particles shRNA containing either 3 targetspecific constructs that encode short hairpin RNA (shRNA) ensured by manufacturer for knockdown IκBα (sc-44265-V) gene expression, or nontargeting control sequences (sc-108080), and a puromycin resistance gene for selection of transduced cells, were purchased from Santa Cruz Biotechnology, Inc. The NF-κB transcriptional activity was assessed using a luciferase reporter plasmid under control of NF-κB binding site (pGL3/NF-κB Luc) from BD Biosciences. For animal studies, the DDB2-overexpressing and control MDA-MB231 cells were rendered fluorescent by transfection with the pWPT-GFP expression vector (Addgene). 
Cell culture, transfections and infections
All human breast cancer cell lines (MCF-7, T47D, MDA-MB231 and SKBR3) cell lines were purchased from EuropeanCollection of Cell Cultures (Sigma) and authentification procedures were by PCR of short tandem repeat sequences within chromosomal microsatellite DNA (STR-PCR). All cell lines were not passaged longer than 6 months after receipt and were cultured in RPMI 1640 medium without phenol red (Invitrogen) supplemented with 10% (v/v) fetal calf serum (Sigma). Cells were transiently transfected with different luciferase reporter plasmids (1 µg), and the pSV40/β-gal plasmid (0.1 µg) expressing β-galactosidase (Invitrogen) as control for transfection efficiency, using JetPEI reagent (Ozyme), and harvested 24 hours after transfection. Cells were stably transfected with 4 µg of pcDNA3(+) expression vector containing the DDB2 open reading frame cDNA, using JetPEI reagent (Ozyme). One day later, the clones were selected with 400 µg/mL of G418 for 4 weeks. Resistant clones were isolated and then screened for DDB2 expression by RT-PCR and Western blot analysis. One week before experiments, cells were placed into complete medium without G418. Transduction-ready lentiviral particles were used at the optimal conditions for efficient cell transduction and gene silencing with puromycin selection, and were determined for MDA-MB231 cells as 2 TU/cell. Two days later, the clones were selected with 1 µg/mL 
Treatment of cell culture
For some experiments (migration and invasion assays), breast tumor cells were treated for 24 hours with 50 μg/mL of SN50 or SN50 control peptide (Santa Cruz Biotechnology, Inc.).
Preparation of total, nuclear and cytoplasmic extracts
Human breast cancer cell lines were lysed in a 10 mM Tris/HCl buffer, pH 7.4, containing 5 mM EDTA, 1% Triton X-100 and a protease inhibitor cocktail, at 4°C for 20 min. After centrifugation at 17,000 x g for 20 min at 4°C, the supernatant was collected as total protein extract. Nuclear and cytoplasmic extracts were prepared with nuclear extract kit according to the manufacturer's instructions (Active Motif). Protein concentrations were determined according to Lowry et al., (8) using bovine serum albumin (BSA) as a standard (Bio-Rad).
Antibodies, western blot and immunocytofluorescence
Antibodies used for western blot and immunocytofluorescence at the optimized dilutions are done in Supplementary Methods. Western blot and detection with chemiluminescent substrate were carried out as described previously (4), with total (50 µg), cytoplasmic (20 µg) and nuclear (15 µg) proteins.
Breast tumor cells were cultured onto glass side for 5 days before confluence. Cells were fixed in 4% paraformaldehyde over 20 min at room temperature, then blocked and permeabilized with PBS containing 2% bovine serum albumin/0.2% Triton X-100. After exposure to the primary polyclonal antibodies diluted at 1:50 for 1 hour at room temperature and three washes in PBS, cells were incubated with the Alexa 594-conjugated secondary antibodies, diluted at 1:100 in PBS containing BSA and Triton X-100 for 1 hour at room 
Gelatin zymography
The enzymatic activities of MMP2 and MMP9 were determined by gelatin zymography.
Breast tumor cells were cultured under normal conditions and then in a serum-free medium for 24 hours with or not 5 µg/mL fibronectin, as described previously (9) . SKBR3 cell medium was supplemented with 25 ng/mL of EGF. The conditioned medium was collected and equal aliquots were analyzed on gelatin substrate gels, as we described in details previously (4) . Gelatinase activities were visible as clear bands, indicative of proteolysis of the substrate protein.
Luciferase assay
The luciferase assays were performed using the luciferase reporter gene assay system and β-galactosidase activity was detected using luminescent β-Gal detection assay (Roche).
Relative luciferase activities were obtained by the ratio of luciferase/β-gal and expressed as mean ± SD from at least three independent experiments, each done in triplicate.
Reverse Transcription-PCR analysis
Gene expression was monitored by semi-quantitative performed as described elsewhere The relative concentration of DDB2, IκBα or MMP9 transcript was calculated using cycle threshold (Ct) values that were derived from a standard curve and normalized to the average Ct values of the Ubiquitin B (UBB) and ribosomal protein large P 0 (RPLP0) internal controls.
Chromatin immunoprecipitation assay (ChIP), electrophoretic mobility shift and supershift assays
Chromatin isolation and enzymatic shearing were carried out using the ChIP-IT Express kit (Active Motif) and immunoprecipitations with either anti-DDB2, anti-p65 NF-κB, antihistone modifications (acetylated on lysine 27 or dimethylated on lysine 4), anti-RNA polymerase II(polII) from Active Motif, and anti-CREB Binding Protein (CBP)/p300
(Abcam) were performed as described previously (3). Electrophoretic mobility shift assay (EMSA) and supershift assay for NF-κB and Sp1 were performed with a 32 P-labeled oligonucleotide representing the respective consensus site as probe, as described previously (10) . EMSA and the supershift assay for DDB2 were carried out as detailed previously (3), with the oligonucleotides representing the region of the IκBα promoter where the binding of DDB2 was detected by ChIP assay (Supplementary Table S1 ). which was first digoxigenin-labeled by a random primer labeling method, as described previously (12) . Digoxigenin was detected using specific alkaline phosphatase-labeled antidigoxigenin polyclonal antibodies from sheep (Roche) with a substrate solution containing 5-bromo-chloro-indolyl phosphate and nitroblue tetrazolium. After the color development, total 
In Vivo
Statistical analysis
The experiments were repeated at least three times. Results were expressed as mean ± SD or SEM, as indicated. All statistical analyses for migration, invasion, luciferase assays, quantitative RT-PCR and Western blot analyses were performed using two-tailed Student's t test (GraphPad Prism 5.0, GraphPad Software, San Diego, CA). For in vivo experiments with animals, statistical analyses were performed using the Mann Whitney test (GraphPad Prism 5.0). In all cases, differences were considered to be statistically significant at a value of p<0.05. were used for the subsequent studies (Fig. 1A) . We next evaluated the motility of MDA-MB231 and SKBR3 cells expressing DDB2 in migration and invasion assays. Both migration and invasion were reduced between 50 and 65% according to the DDB2-expressing cell clones, as compared with control Neo cells (Fig. 1B-D) . Similar results were obtained using wound healing-induced migration assay ( Supplementary Fig. S1 ). Inversely, knockdown of endogenous DDB2 in noninvasive T47D cell line induced migratory and invasive features ( Supplementary Fig. S2 ). We also evaluated the secretion of MMP2 and MMP9, which are related to migration and invasion abilities of metastatic breast tumor cells (13) . Zymographic analyses were carried out in the presence or absence of fibronectin, which has been reported to activate rapidly pro-MMP2 (72 kDa) and pro-MMP9 (92 kDa) (9) .Overexpression of DDB2 decreased significantly pro-and mature MMP9 (82 kDa) but not pro-and mature MMP2 (64 kDa) secretion in MDA-MB231 cells with or without fibronectin, as compared to control cells (Fig. 1E) . These results were confirmed with HER2-positive SKBR3 cells cultured in the presence of epithelial growth factor or EGF (Fig. 1E ). expression and the histological SBR grade in a cohort of 92 samples from patients with breast carcinoma (Supplementary Figure S3) .
DDB2 overexpression is associated with a decrease in the constitutive NF-κB activity
As we observed a decrease in the secretion of MMP9 in aggressive DDB2-overexpressing tumor cells, and this gene is regulated by NF-κB (14, 15), we verified if DDB2 influenced the activity of this transcription factor. The transcriptional activity of NF-κB was evaluated using a luciferase reporter gene system under the control of a κB motif. Whereas NF-κB activity was increased by 2.0-to 4.6-fold in DDB2 shRNA-transfected T47D cells ( Supplementary   Fig. S2 ), it was decreased by 2.7-and 8.0-fold in DDB2-overexpressing MDA-MB231 and SKBR3 cells, respectively, in contrast to the respective control cells (Fig. 3A) . This decrease in NF-κB activity was the consequence of a strong decrease in p65NF-κB nuclear translocation in DDB2-overexpressing cells, as seen by Western blotting with cytoplasmic and nuclear extracts as well as cytoimmunofluorescence ( Fig. 3B and C) . Only in DDB2-overexpressing SKBR3 cells was the p50NF-κB nuclear translocation decreased markedly. In addition, this decrease in NF-κB activity was also associated with a strong increase in the IκBα protein level in the cytoplasmic extract from DDB2-overexpressing cells, in contrast to control cells (Fig. 3C ). This latter observation was the consequence of an increase in IκBα protein level in DDB2-overexpressing cells, in contrast to control Neo cells (Fig. 4) . IκBα mRNA level was increased in DDB2-overexpressing cells in contrast to control Neo cells ( Fig. 5A and B) . However, we observed a decrease in the MMP9 mRNA in DDB2-overexpressing cells according to the decrease in NF-κB activity, compared to control cells.
DDB2 decreases NF-κB activity through its role in transcriptional IκBα gene expression
Then, the occupancy of the IκBα promoter by DDB2 was investigated by ChIP experiments with MDA-MB231 cells, using different sets of primers which delineated four regions covering 1.4 kb of the proximal promoter of the IκBα gene ( Fig. 5C and Supplementary Table S1 ). The results showed that specific binding of DDB2 to region III (between -555 and -394 bp from initiation transcription site) only was observed in DDB2-overexpressing cells, in contrast to control Neo cells, indicating that the protein binds to the IκBα promoter gene (Fig.   5D ). Interestingly, p65NF-κB was detected in region IV, containing a well known NF-κB binding site (16) , in contrast to DDB2-overexpressing cells. We analyzed by ChIP if DDB2 binding to the IκBα proximal promoter was associated with an epigenetic process such as posttranslational histone modifications and recruitment of CBP/p300. Whereas no differences were observed in the acetylation as well as methylation of H3 histone to the lysine residues 27 and 4, respectively between MDA-MB231 cells expressing or not DDB2, the presence of the p300 protein was more detected for DDB2-overexpressing cells (Fig. 5E ).
To identify precisely the sequence of the DDB2 binding site, a set of six oligonucleotides named O 1 to O 6 and corresponding to region III determined by ChIP assay were used for EMSA (Supplementary Table S1 ). Among them, only the O 3 oligonucleotide formed a shifted DNA-protein complex in DDB2-overexpressing MDA cells compared with control cells (Fig.   6A ), which was specific, as shown competition experiment using different amounts of unlabeled O 3 probe and a nonspecific NF-κB probe (Fig. 6B) . The presence of DDB2 was detected on the O 3 oligonucleotide by a marked decrease in its DNA binding activity by supershift experiment using specific polyclonal antibodies (Fig. 6C) . The shift formed with the O 5 oligonucleotide was verified as nonspecific by competition using different amounts of (Fig. 6E) . These results were confirmed with MCF-7 cells, which overexpress naturally DDB2 ( Supplementary   Fig. S4 ).
DDB2 reduces the invasive potential of aggressive breast tumor cells through its negative control of NF-κB activity
To evaluate whether DDB2 reduced the migratory and invasive abilities of aggressive breast tumor cells by inducing IκBα gene, this latter was knocked down in DDB2-overexpressing MDA-MB231 cells, using lentiviral short hairpin RNAs (shRNAs). Two DDB2-overexpressing cell clones transfected with shRNA IκBα were isolated (Fig. 7A) , in which NF-κB activity, MMP9 expression, and migratory and invasive abilities were restored in part 
Discussion
We observed previously that DDB2 expression was inversely correlated with the invasive properties of breast tumor cells, and that a constitutive overexpression of DDB2 in nonmetastatic cells induced cell proliferation by activating the G1/S transition phase of the cell cycle (2) . In the present study, our findings summarized in Fig. 7F provide for the first time strong evidence that DDB2 plays a role as a negative regulatory factor in the invasive abilities of breast tumor cells in vitro as well as in vivo. We demonstrated that DDB2 plays this role via decreasing NF-κB activity, by its involvement in the regulation of the IκBα gene.
Several studies have reported that NF-κB plays also a key role in the induction of invasive abilities of cancer cells and is required for maintenance of the malignant phenotype, particularly for breast cancer cells. Inhibition of the NF-κB pathway abrogates generation of the Ras-dependent invasive phenotype acquired by breast cancer cells in vitro and prevents metastasis in a mouse model (17) . In accordance with this study, inhibition of the constitutive or induced NF-κB pathway in MDA-MB231 and HER2 positive SKBR3 cells, respectively, using the SN50 peptide (18) , decreased migration and invasion of these cells ( Supplementary   Fig. S5 ). The NF-κB-dependent acquisition of invasive properties of breast cancer cells and tumors as well as of carcinogen-induced primary rat mammary tumors is often associated with an aberrant constitutive activation of this transcription factor (6, 19) . Two molecular mechanisms have been identified to be related to the constitutive activation of NF-κB in breast cancer cells. An aberrant expression of IκB kinases and casein kinase II was observed in some human breast cancer cells and primary tumors, which was responsible for constitutive NF-κB activation by controlling IκBα stability (20) . It has been reported also that the constitutive activation of NF-κB could be due to an enhanced expression of NF-κB-inducing kinase involved in the activation of IκB kinases, resulting to an epigenetic alteration of its gene in the malignant basal-like breast cancer (21) . Concerning HER2-positive breast cancer CAN-12-3655 cells, as the SKBR3 cell line, NF-κB is activated constitutively by the survival signalling pathway via PI3K/Akt and NIK/IκB kinase, which is triggered by the binding of EGF to its overexpressed membrane receptor (22) . This may explain the marked effect of DDB2 on NF-κB activity and the migration/invasion properties of EGF-sensitive SKBR3 cells. In the present study, we identified for the first time a new molecular mechanism corresponding to a lack of DDB2 expression in aggressive breast cancer cells, which leads to a low IκBα expression and a high constitutive NF-κB activity.
NF-κB plays a causal role in migration and invasion of tumor cells by regulating positively target genes. Among them, the gene encoding MMP9 is a well known target gene of NF-κB, whose promoter contains a NF-κB site at -599 bp from the transcription start site (14) . MMP9, a type IV collagenase, is partly responsible for the invasive phenotype of tumor cells, by degrading the basement membrane (7). In addition, MMP9 expression is correlated often with advanced tumor grade in breast cancer (23) . The fact that MMP9 expression is reduced by the DDB2-dependent decrease in NF-κB activity could explain in part that DDB2 plays a negative role in the invasive properties of aggressive tumor cells. It is not excluded that DDB2 plays this role by maintaining a low expression of the MnSOD gene, via its binding to the proximal promoter, as we demonstrated recently (3). MnSOD, which is constitutively overexpressed in highly invasive breast tumor cells, participates in the invasive properties of these cells by increasing the level of secreted MMP9 via the hydrogen peroxide produced from its enzymatic activity on the superoxide anion (4).
We identified that the involvement of DDB2 in the regulation of the IκBα gene is the molecular mechanism by which DDB2 plays a negative role in the invasive abilities of modifications, regardless of the DDB2 expression. Only the p300 protein was detected more at region IV close to the transcription start site in DDB2-overexpressing cells than in control cells, which may explain the DDB2-dependent increase in IκBα expression. Indeed, the CBP/p300 family is well known to enhance transcription, not only by modifying chromatin structure through its histone acetyltransferase activity, but also by facilitating the assembly of activating transcription complexes at the promoter (26) . In addition, these proteins are able to interact with a variety of proteins, including DDB2, to increase their activity as co-activators of transcription (27) . 
